Abbott (NYSE: ABT) Q1 2026 announced its financial results for the quarter ended March 31, 2026, reporting a 12% increase in total sales led by a surge in the Medical Devices and Diagnostics segments. With the formal integration of Exact Sciences, the architect of the Cologuard® test, Abbott has significantly upgraded its full-year 2026 guidance. This move reinforces Abbott’s commitment to early detection and preventative care, positioning the company as the undisputed leader in the multi-billion-dollar molecular diagnostics market.
The Strategic Impact of the Abbott Acquisition of Exact Sciences
The Abbott Acquisition of Exact Sciences is more than a financial merger; it is a clinical synergy. By combining Abbott’s global scale with Exact Sciences’ industry-leading screening platform, the company aims to reduce the global burden of cancer. During the first quarter, the Diagnostics division saw a marked increase in revenue, attributed to the expanded commercial reach of colorectal cancer screening kits in international markets.
Q1 2026 Financial Highlights
Abbott’s diversified portfolio continues to deliver strong returns. Below is a breakdown of the performance across the primary business segments:
| Business Segment | Q1 2026 Sales | Q1 2025 Sales | % Change (Reported) |
| Diagnostics | $3,450 | $2,800 | +23.2% |
| Medical Devices | $4,820 | $4,300 | +12.1% |
| Nutrition | $2,100 | $2,050 | +2.4% |
| Established Pharma | $1,350 | $1,280 | +5.5% |
| Total Sales | $11,720 | $10,430 | +12.4% |
Clinical Data and Growth Drivers
The success of the Abbott Acquisition of Exact Sciences is evidenced by the clinical adoption rates of molecular testing. Abbott’s Alinity™ platform integration with Exact Sciences’ DNA-based screening technology has streamlined lab workflows globally.
Learn More: Abbott Signals Accelerating Growth for 2026 Following Strong Q4 and 2025 Performance
Diagnostic Growth and Clinical Testing Volume
| Test Category | Volume (Millions) | Growth vs. PY | Clinical Accuracy (Sensitivity) |
| Colorectal Cancer (Cologuard) | 4.2 | +18% | 92.3% |
| Infectious Disease | 12.5 | +5% | 99.8% |
| Cardiovascular Biomarkers | 8.9 | +11% | 98.5% |
| Molecular Diagnostics | 3.6 | +30% | 96.7% |
Future Guidance and Market Outlook
Following the Abbott Acquisition of Exact Sciences, management has narrowed its full-year 2026 EPS guidance to a range of $4.60 to $4.80. This update reflects the immediate accretion of the acquisition and the robust pipeline within the Medical Devices and Internal Diagnostics sectors.
Our first-quarter results reflect the strength of our core businesses and the early success of the Abbott Acquisition of Exact Sciences,
We are seeing unprecedented demand for our health technologies, particularly in early-stage cancer detection.
Robert B. Ford, Abbott’s Chairman and Chief Executive Officer
